Molecular Profiling and Biomarker Testing

Molecular profiling and biomarker testing have transformed oncology diagnosis and treatment selection by identifying the specific genetic, protein, and cellular characteristics that drive individual tumors. This page covers how these tests work, the major testing platforms available, the clinical contexts in which they are ordered, and the boundaries that define when results guide treatment versus when they remain investigational. Understanding this landscape is essential to interpreting what oncology encompasses and how precision medicine fits within it.

Definition and scope

Molecular profiling is the systematic analysis of a tumor's molecular features — including DNA mutations, gene expression patterns, protein expression, and chromosomal alterations — to characterize its biological behavior and predict its response to therapy. Biomarker testing is the broader category under which molecular profiling falls; a biomarker is any measurable biological indicator associated with a disease process, pharmacological response, or clinical outcome.

The U.S. Food and Drug Administration (FDA) formally defines companion diagnostic devices as in vitro diagnostics that provide essential information for the safe and effective use of a corresponding drug or biological product (FDA Companion Diagnostics). As of 2024, the FDA had approved more than 45 companion diagnostic tests paired with specific oncology therapies, making regulatory alignment between test and treatment a central feature of this field.

Biomarkers in oncology are classified into four functional categories:

1. Predictive biomarkers — identify patients likely to respond to a specific therapy (e.g., EGFR exon 19 deletion predicting response to erlotinib in non-small cell lung cancer).
2. Prognostic biomarkers — indicate the likely disease course independent of treatment (e.g., TP53 mutation burden in certain hematologic malignancies).
3. Pharmacodynamic biomarkers — confirm that a drug is having its intended biological effect.
4. Minimal residual disease (MRD) markers — detect residual cancer cells below standard imaging or pathology thresholds.

How it works

Molecular profiling begins with tissue acquisition — typically a biopsy specimen processed into formalin-fixed paraffin-embedded (FFPE) blocks or a liquid biopsy blood sample. The College of American Pathologists (CAP) publishes laboratory accreditation checklists (CAP Accreditation) that govern pre-analytic handling, and the Clinical Laboratory Improvement Amendments (CLIA), administered by the Centers for Medicare & Medicaid Services (CMS), set federal standards for all laboratories performing molecular testing (CMS CLIA Program).

The primary testing platforms used in clinical oncology include:

• Immunohistochemistry (IHC) — detects protein expression using antibodies on tissue sections; commonly used for PD-L1, HER2, and hormone receptor status. IHC results are semiquantitative and scored on standardized scales (e.g., HER2 0–3+, with 3+ indicating overexpression).
• Fluorescence in situ hybridization (FISH) — identifies gene amplifications and chromosomal translocations at the single-cell level; used to confirm equivocal HER2 IHC results and to detect ALK and ROS1 fusions.
• Polymerase chain reaction (PCR) and RT-PCR — amplifies specific gene sequences for mutation detection; the BCR-ABL1 quantitative PCR in chronic myeloid leukemia is a standard MRD monitoring tool.
• Next-generation sequencing (NGS) — simultaneously sequences hundreds to thousands of genes from a single sample; comprehensive genomic profiling (CGP) panels such as FoundationOne CDx can identify substitutions, insertions/deletions, copy number alterations, and structural rearrangements across 324 or more genes.
• Liquid biopsy — analyzes circulating tumor DNA (ctDNA) from peripheral blood; FDA-approved platforms include the Guardant360 CDx for EGFR mutation detection in lung cancer.

Tumor mutational burden (TMB) and microsatellite instability (MSI) status are derived from NGS data and serve as tissue-agnostic predictive biomarkers for immune checkpoint inhibitor response. The FDA approved pembrolizumab for TMB-high solid tumors (≥10 mutations per megabase) in 2020, representing the first tumor-agnostic approval based on a quantitative genomic threshold (FDA Press Announcement).

Common scenarios

Molecular profiling is ordered across a range of clinical presentations. The most established applications include:

• Non-small cell lung cancer (NSCLC): National Comprehensive Cancer Network (NCCN) guidelines for NSCLC recommend broad molecular profiling at diagnosis including EGFR, ALK, ROS1, BRAF, KRAS G12C, MET, RET, NTRK, PD-L1, and TMB/MSI status (NCCN Guidelines).
• Breast cancer: HER2 status, estrogen receptor (ER), and progesterone receptor (PR) testing are standard. Multigene expression assays (e.g., Oncotype DX 21-gene recurrence score) stratify chemotherapy benefit in early-stage, hormone receptor-positive disease.
• Colorectal cancer: RAS (KRAS and NRAS) and BRAF V600E mutation testing determines eligibility for anti-EGFR therapies. MSI-H/dMMR status identifies candidates for immunotherapy, as discussed under colorectal cancer treatment considerations.
• Hematologic malignancies: Chromosome banding, FISH, and PCR define risk stratification and therapy selection in leukemia and lymphoma.

Liquid biopsy has specific utility when tissue is insufficient for standard profiling, when monitoring for acquired resistance mutations during targeted therapy, and for serial ctDNA surveillance after definitive treatment.

Decision boundaries

Molecular profiling results operate within defined regulatory and clinical thresholds that determine whether a result is actionable, investigational, or incidental. The regulatory context for oncology establishes the federal framework governing test approval, reporting, and therapeutic pairing.

A result is considered clinically actionable when a validated companion diagnostic has FDA approval paired with a specific therapy for the tumor type and biomarker combination in question. Results from genes with variants of uncertain significance (VUS) do not meet this threshold; NCCN and the Association for Molecular Pathology (AMP) classify VUS findings as requiring re-evaluation as evidence accumulates rather than immediate treatment change (AMP Guidelines).

Germline versus somatic testing boundaries require careful delineation. Somatic mutations detected on tumor NGS panels may indicate an underlying germline pathogenic variant — particularly in BRCA1/2, MLH1, MSH2, and TP53 — triggering referral to genetic counseling as addressed under genetic testing and cancer risk. Laboratories are not uniformly required to report germline findings from somatic panels, and institutional policies vary under CLIA/CAP frameworks.

Pathology report interpretation, covered in detail under pathology reports, integrates molecular profiling data with histologic findings to produce the composite diagnostic picture that informs treatment planning. When molecular findings are ambiguous or discordant with histology, multidisciplinary tumor board review is the standard mechanism for resolution rather than unilateral oncologist interpretation.

References

• FDA Companion Diagnostics — U.S. Food and Drug Administration
• FDA Oncology Drug Approvals — U.S. Food and Drug Administration
• CMS Clinical Laboratory Improvement Amendments (CLIA) — Centers for Medicare & Medicaid Services
• CAP Laboratory Accreditation Program — College of American Pathologists
• NCCN Clinical Practice Guidelines in Oncology — National Comprehensive Cancer Network
• AMP Publications and Guidelines — Association for Molecular Pathology
• NCI Dictionary of Cancer Terms – Biomarker — National Cancer Institute

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)